Defective TGF-β signaling in bone marrow-derived cells prevents hedgehog-induced skin tumors

Cancer Research

Volumn 74, Issue 2, 2014, Pages 471-483

  Fan, Qipeng ^a   Gu, Dongsheng ^a   Liu, Hailan ^a   Yang, Ling ^a   Zhang, Xiaoli ^a   Yoder, Mervin C ^a   Kaplan, Mark H ^a   Xie, Jingwu ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2 ANTAGONIST; MONOCYTE CHEMOTACTIC PROTEIN 1; SONIC HEDGEHOG PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL CELL CARCINOMA; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CANCER CELL; CARCINOGENESIS; CELL MIGRATION; CELL POPULATION; CONTROLLED STUDY; IMMUNE DEFICIENCY; IN VITRO STUDY; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROCESSING; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; SKIN CELL; SKIN TUMOR; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ANIMALS; BONE MARROW CELLS; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CCL2; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; IMMUNOSUPPRESSIVE AGENTS; KERATINOCYTES; MICE; MICE, TRANSGENIC; MYELOID CELLS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, CCR2; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; T-LYMPHOCYTES; TISSUE DISTRIBUTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84892942306     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2134-T     Document Type: Article

References (45)

1. Shiao SL, Ganesan AP, Rugo HS, Coussens LM. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev 2011;25:2559-72.
2. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012;21:309-22.
3. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
5. Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen SH. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol 2011;77:12-9.
6. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 2012;22:275-81.
7. Sonda N, Chioda M, Zilio S, Simonato F, Bronte V. Transcription factors in myeloid-derived suppressor cell recruitment and function. Curr Opin Immunol 2011;23:279-85.
8. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008;8:743-54.
9. Ng JM, Curran T. The Hedgehog's tale: developing strategies for targeting cancer. Nat Rev Cancer 2011;11:493-501.
10. Ingham PW. Hedgehog signaling: a tale of two lipids. Science 2001;294:1879-81.
11. Lum L, Beachy PA. The Hedgehog response network: sensors, switches, and routers. Science 2004;304:1755-9.
12. Yang L, Xie G, Fan Q, Xie J. Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene 2010;29:469-81.
13. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 2011;32:19-25.
14. Toh B, Wang X, Keeble J, Sim WJ, Khoo K, Wong WC, et al. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol 2011;9:e1001162.
15. Fan Q, He M, Sheng T, Zhang X, Sinha M, Luxon B, et al. Requirement of TGF{beta} Signaling for SMO-mediated Carcinogenesis. J Biol Chem 2010;285:36570-6.
16. Chen M, O'Connor KL. Integrin alpha6beta4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells. Oncogene 2005;24:5125-30.
17. MitchellL A, Henderson AJ, Dow SW. Suppressionof vaccineimmunity by inflammatory monocytes. J Immunol 2012;189:5612-21.
18. Nam BY, Paeng J, Kim SH, Lee SH, Kim do H, Kang HY, et al. The MCP-1/CCR2 axis in podocytes is involved in apoptosis induced by diabetic conditions. Apoptosis 2012;17:1-13.
19. Sun X, Charbonneau C, Wei L, Yang W, Chen Q, Terek RM. CXCR4-targeted therapy inhibits VEGF expression and chondrosarcoma angiogenesis and metastasis. Mol Cancer Ther 2013;12:1163-70.
20. Gu D, Fan Q, Zhang X, Xie J. A role for transcription factor STAT3 signaling in oncogene smoothened-driven carcinogenesis. J Biol Chem 2012;287:38356-66.
21. Mao J, Ligon KL, Rakhlin EY, Thayer SP, Bronson RT, Rowitch D, et al. A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res 2006;66:10171-8.
22. Grachtchouk M, Pero J, Yang SH, Ermilov AN, Michael LE, Wang A, et al. Basal cell carcinomas in mice arise from hairfollicle stem cells and multiple epithelial progenitor populations. J Clin Invest 2011;121:1768-81.
23. Wang GY, Wang J, Mancianti ML, Epstein EH Jr. Basal cell carcinomas arise from hair follicle stem cells in Ptch1 (+/-) mice. Cancer Cell 2011;19:114-24.
24. Haverkamp JM, Crist SA, Elzey BD, Cimen C, Ratliff TL. In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. Eur J Immunol 2011;41:749-59.
25. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010;207:2439-53.
26. Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-beta targeted cancer therapy. Int J Biol Sci 2012;8:964-78.
27. He W, Cao T, Smith DA, Myers TE, Wang XJ. Smads mediate signaling of the TGFbeta superfamily in normal keratinocytes but are lost during skin chemical carcinogenesis. Oncogene 2001;20:471-83.
28. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol 2012;13:616-30.
29. Biswas S, Chytil A, Washington K, Romero-Gallo J, Gorska AE, Wirth PS, et al. Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer. Cancer Res 2004;64:4687-92.
30. Zhang J, He XC, Tong WG, Johnson T, Wiedemann LM, Mishina Y, et al. Bone morphogenetic protein signaling inhibits hairfollicle anagen nduction by restricting epithelial stem/progenitor cell activation and expansion. Stem Cells 2006;24:2826-39.
31. Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science 1995;269:1427-9.
32. Srour EF, Yoder MC. Flow cytometric analysis of hematopoietic development. Methods Mol Med 2005;105:65-80.
33. Macleod AS, Havran WL. Functions of skin-resident gammadelta T cells. Cell Mol Life Sci 2011;68:2399-408.
34. Mirzadegan T, Diehl F, Ebi B, Bhakta S, Polsky I, McCarley D, et al. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle. J Biol Chem 2000;275:25562-71.
35. Domanska UM, Timmer-Bosscha H, Nagengast WB, Oude Munnink TH, Kruizinga RC, Ananias HJ, et al. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia 2012;14:709-18.
36. Yiakouvaki A, Dimitriou M, Karakasiliotis I, Eftychi C, Theocharis S, Kontoyiannis DL. Myeloid cell expression of the RNA-binding protein HuR protects mice from pathologic inflammation and colorectal carcinogenesis. J Clin Invest 2012;122:48-61.
37. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013;13:739-52.
38. Novitskiy SV, Pickup MW, Chytil A, Polosukhina D, Owens P, Moses HL. Deletion of TGF-beta signaling in myeloid cells enhances their antitumorigenic properties. J Leukoc Biol 2012;92:641-51.
39. Forrester E, Chytil A, Bierie B, Aakre M, Gorska AE, Sharif-Afshar AR, et al. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res 2005;65:2296-302.
40. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008;13:23-35.
41. Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, et al. TGF-betamiR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell 2012;22:291-303.
42. Strainic MG, Shevach EM, An F, Lin F, Medof ME. Absence of signaling into CD4 (+) cells via C3aR and C5aR enables autoinductive TGF-beta1 signaling and induction of Foxp3 (+) regulatory T cells. Nat Immunol 2013;14:162-71.
43. Schlenner SM, Weigmann B, Ruan Q, Chen Y, von Boehmer H. Smad3 binding to the foxp3 enhancer is dispensable for the development of regulatory T cells with the exception of the gut. J Exp Med 2012;209:1529-35.
44. Xiang X, Poliakov A, Liu C, Liu Y, Deng ZB, Wang J, et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer 2009;124:2621-33.
45. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010;10:554-67.